Anti-Infectives · LP-035
Doxycycline Capsules
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-035Anti-Infectives
- Generic identity
- DoxycyclineCapsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-035
- Generic identity
- Doxycycline
- Presentation
- Capsule
- Catalogue strength
- 100 mg
- Catalogue pack
- Blister 10 x 10 capsules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: doxycycline.
- Dosage form: capsule.
- Catalogue strength: 100 mg.
- Catalogue pack: blister 10 × 10 capsules.
Layer 02 · Unresolved product-specific fields
- Exact doxycycline chemical form/basis and quantitative capsule composition.
- Capsule shell/fill characteristics and whether opening/dispersing is permitted.
- Approved indication, age/pregnancy precautions, administration instructions and interaction warnings for the exact product.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100 mg | Capsule | — | Blister 10 × 10 capsules | Chemical form, exact formula and approved administration instructions are not established. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Doxycycline is a tetracycline antibiotic with a role in selected bacterial infections and other specifically assessed clinical settings. An oral capsule is a systemic medicine, with interactions and precautions that differ from topical treatments. The relevant diagnosis, local resistance and patient circumstances determine its use. This educational background does not establish an approved Luang Pharma indication, a prevention claim or suitability for a particular age group.
Clinical context and therapeutic role
A prescriber considers the suspected organism, site of infection and whether doxycycline is appropriate within current guidance. Acne-related use, treatment of systemic infections and other clinical contexts require different professional decisions. Pregnancy, age and ability to swallow a capsule are relevant. Mineral supplements, antacids and other medicines may interfere with treatment. Persistent symptoms should prompt reassessment rather than an assumption that a longer course will solve the problem.
Selected safety context
Doxycycline can irritate or ulcerate the esophagus, cause photosensitivity and lead to gastrointestinal upset. Administration technique is therefore important and should follow the leaflet. Severe headache with visual disturbance needs urgent review because raised intracranial pressure is a possible concern. Pregnancy and use in children need condition-specific assessment. Iron, calcium, magnesium-containing products and some other medicines interact. Severe allergy, blistering rash or significant diarrhoea requires medical attention.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes an oral capsule. Capsule shell, fill composition and release behavior are product-specific and are not established by the ingredient name. Opening a capsule or dispersing its contents should be considered only when the approved instructions or a pharmacist confirms that this is appropriate.
Retain the original labeled pack and check its integrity and expiry before use. Storage requirements must come from the supplied product information; no shelf life or temperature is inferred here. A pharmacist can advise on an alternative presentation if swallowing is difficult.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: DoxycyclineArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 5 September 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-035.
Professional enquiries
Request product-specific evidence for LP-035.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.